Aditxt's subsidiary Persanta has taken a significant step toward commercializing its innovative cancer detection technology by engaging Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO).
The planned IPO, scheduled for the second half of 2025, aims to accelerate Persanta's commercial launch efforts both in the United States and internationally. At the heart of this initiative is the company's proprietary Mitomic® Technology platform, which represents a novel approach to early cancer detection and diagnosis.
Revolutionary Blood-Based Cancer Detection
Persanta's technology stands out in the cancer diagnostics landscape by utilizing a non-invasive blood-based testing approach. The platform's distinctive feature lies in its use of mitochondrial DNA deletions as biomarkers for disease detection, offering a unique methodology for identifying malignancies at earlier stages when treatment outcomes typically show greater success.
Broad Clinical Applications
The company's biomarker portfolio demonstrates significant versatility, encompassing multiple high-clinical need cancers. Beyond oncology, the technology shows promise for broader medical applications, suggesting potential expansion into other disease areas.
Strategic Commercialization Plans
The IPO proceeds are earmarked for two primary objectives:
- Funding the U.S. launch of Laboratory Developed Tests (LDTs) for early cancer detection
- Expanding global reach through distribution partnerships and securing key international regulatory approvals
This strategic approach reflects Persanta's commitment to making its innovative diagnostic technology widely accessible while building a strong commercial foundation in both domestic and international markets.
